Gelonghui, March 22丨Dongrui Pharmaceutical (02348.HK) announced that for the year ended December 31, 2023, the company recorded revenue of about RMB 1.15 billion, a year-on-year decrease of about 9.9%. Profit attributable to owners of parent companies was approximately RMB 326 million, a year-on-year decrease of approximately 9.0%. The Board recommended a year-end dividend of HK$0.065 per share.
东瑞制药(02348.HK)年度母公司拥有人应占溢利约3.26亿元 同比下降约9.0%
The annual profit attributable to owners of Dongrui Pharmaceuticals (02348.HK) was about 326 million yuan, a year-on-year decrease of about 9.0%
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.